Dark Forest Capital Management LP Macrogenics Inc Transaction History

Dark Forest Capital Management LP

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$9.77 - $21.47 $116,184 - $255,321	11,892 New	11,892 $175,000
Q1 2023 May 12, 2023	BUY	$4.82 - $7.24 $6,603 - $9,918	1,370 New	1,370 $9,000
Q3 2022 Nov 14, 2022	SELL	$3.01 - $5.22 $11,149 - $19,334	-3,704 Reduced 95.74%	165 $1,000
Q2 2022 Aug 15, 2022	BUY	$2.25 - $9.99 $8,705 - $38,651	3,869 New	3,869 $11,000
Q1 2022 May 13, 2022	SELL	$8.12 - $16.9 $3,621 - $7,537	-446 Closed	0 $0
Q4 2021 Feb 11, 2022	BUY	$15.91 - $21.88 $7,095 - $9,758	446 New	446 $7,000
Q3 2021 Nov 12, 2021	SELL	$19.74 - $28.7 $154,544 - $224,692	-7,829 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$20.49 - $35.63 $160,416 - $278,947	7,829 New	7,829 $210,000

132

55.4M

215K

238K

Ticker MGNX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 61,458,800
Market Cap $209M
Description
MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients ...

Get notified when there are updates to the investment portfolio of Dark Forest Capital Management LP, based on Form 13F filings with the SEC.

Stay updated on Dark Forest Capital Management LP with notifications on news.